Potential for immunotherapy with heat-killed Mycobacterium vaccae in respiratory medicine

Immunotherapy

Volumn 1, Issue 6, 2009, Pages 933-947

  Stanford, John ^a   Stanford, Cynthia ^a   Dlugovitzky, Diana ^b   Fiorenza, Gladys ^b   Martinel Lamas, Diego ^b   Selenscig, Dante ^b   Bogue, Christina ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^c Hospital I Carrasco   (Argentina)

Author keywords

Bronchospasm; Immune modulation; Immunotherapy; Lung cancer; Mycobacterium vaccae; Respiratory disease; Tuberculosis

Indexed keywords

ETHAMBUTOL; IMMUNOMODULATING AGENT; ISONIAZID; PLACEBO; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY; CONTROLLED STUDY; HUMAN; IMMUNOTHERAPY; LUNG ADENOCARCINOMA; LUNG TUBERCULOSIS; MEDICINE; MYCOBACTERIUM VACCAE; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY SYSTEM; TREATMENT RESPONSE;

BACTERIAL VACCINES; CELLS, CULTURED; CYTOKINES; HUMANS; IMMUNOTHERAPY, ACTIVE; LEUKOCYTES, MONONUCLEAR; MYCOBACTERIUM; NEUTROPHILS; PULMONARY MEDICINE; RECEPTORS, INTERLEUKIN-8B; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TH1-TH2 BALANCE; TUBERCULOSIS, PULMONARY;

EID: 77953386628     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.09.62     Document Type: Article

References (82)

1. Bahr GM, Shaaban MA, Gabriel M et al.: Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae. Tubercle 71, 259-266 (1990). •• Compares different preparations of Mycobacterium vaccae in relation to their ability to induce immunological changes of apparent benefit in the treatment of tuberculosis.
2. Corlan E, Marica C, Macavei C, Stanford JL, Stanford CA: Immunotherapy with Mycobacterium vaccae. 1. In the treatment of newly diagnosed pulmonary tuberculosis in Romania. Respir. Med. 91, 13-19 (1997).
3. Corlan E, Marica C, Macavei C, Stanford JL, Stanford CA: Immunotherapy with Mycobacterium vaccae. 2. In the treatment of chronic or relapsed tuberculosis in Romania. Respir. Med. 91, 21-29 (1997).
4. Onyebujoh P, Abdulmumini T, Robinson S, Rook GAW, Stanford JL: Immunotherapy for tuberculosis in African conditions. Respir. Med. 89, 199-207 (1995). • First evidence that immunotherapy for tuberculosis with M. vaccae can work in HIV-infected patients and suggests that there could be a beneficial effect on HIV itself.
5. Dlugovitzky D, Bottasso O, Dominino JC et al.: Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172). Respir. Med. 93, 557-562 (1999). (Pubitemid 29476265)
6. Johnson JL, Kamya RM, Okwera A et al.: Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration. J. Infect. Dis. 181, 1304-1312 (2000).
7. Dlugovitzky D, Fiorenza G, Farroni M, Bogue C, Stanford C, Stanford J: Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis. Respir. Med. 100, 1079-1087 (2006). •• Detailed, though small, study of three doses of M. vaccae against pulmonary tuberculosis. Clinical, haematological, radiological and immunological improvement are all recorded. It was from this study that the stored material for the current paper was obtained.
8. Ramu G, Grange J, Stanford J: Evaluation of adjunct immunotherapy with killed Mycobacterium vaccae in the treatment of multibacillary leprosy and erythema nodosum leprosum. In: Clinical Mycobacteriology. Casal M (Ed.), Barcelona, Prous Science Publishers, Barcelona, Spain 393-402 (1998).
9. Camporota L, Corkhill A, Long H et al.: The effects of Mycobacterium vaccae on allergen-induced airway responses in atopic asthma. Eur. Respir. J. 21, 287-293 (2003).
10. Hopkin JM, Ferry B, Coull P et al.: Mycobacterial immunization in grass pollen asthma and rhinitis. Thorax 53, 63 (1998).
11. Arkwright PD, David TJ: Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J. Allergy Clin. Immunol. 107, 531-534 (2001).
12. Lehrer A, Bressanelli A, Wachsmann V et al.: Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis. FEMS Immunol. Med. Microbiol. 21, 71-77 (1998).
13. Stanford JL, Stanford CA, O'Brien M, Grange JM: Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur. J. Cancer 44, 224-227 (2008). •• Important paper describing how several doses of M. vaccae can significantly lengthen survival in patients with advanced adenocarcinoma of the lung, while having no such effect in patients with squamous carcinoma of the lung.
14. Berth-Jones J, Arkwright PD, Marasovic D, et al.: Killed Mycobacterium vaccae suspension in children with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Clin. Exp. Allergy. 36(9), 1115-1121 (2006).
15. Davies MG, Symons C, Shaw S, Kaminski ER: An open study to assess the efficacy clinically and immunologically of M. vaccae vaccine in patients with atopic dermatitis. J. Dermatolog. Treat. 17(2), 74-77 (2006).
16. Stanford JL, Stanford CA, Grange JM: Environmental echoes. Sci. Prog. 84, 105-124 (2001). •• Explains how relationships with environmental mycobacteria change with time and the potential influence this could have on the prevalence of disease and the efficacy of bacterial immunotherapeutics.
17. Durban Immunotherapy Trial Group: Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Lancet 354, 116-119 (1999).
18. de Bruyn G, Garner P: Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database Syst. Rev. CD001166 (2003).
19. Mwinga A, Nunn A, Ngwira B et al.: Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 360, 1050-1055 (2002).
20. Hernandez-Pando R, Pavon L, Arriaga K, Orozco H, Madrid-Marina V, Rook G: Pathogenesis of tuberculosis exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Infect. Immun. 65(8), 3317-3327 (1997).
21. Zuany-Amorim C, Sawicka E, Manlius C et al.: Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat. Med. 8, 625-629 (2002).
22. Valian HK, Kenedy LKA, Rostami MN, Mohammadi AM, Khamesipour A: Role of Mycobacterium vaccae in the protection induced by first generation Leishmania vaccine against murine model of leishmaniasis. Parasitol. Res. 103, 21-28 (2008).
23. Hrouda D, Souberbielle BE, Kayaga J, Corbishley CM, Kirby RS, Dalgleish G: Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer. Br. J. Urol. 82(6), 870-876 (1998).
24. Fontanella GH, Pascutti MF, Daurelio L et al.: Improved outcome of Trypanosoma cruzi infection in rats following treatment in early life with suspensions of heat-killed environmental Actinomycetales. Vaccine 25, 3492-3500 (2007). (Pubitemid 46527982)
25. Luo Y: The immunotherapeutic effect of Mycobacterium vaccae vaccine on initially treated pulmonary tuberculosis. Chin. J. Evid. Based Med. 24, 43-47 (2001).
26. Luo YA, Lu SH, Guo SL et al.: Immunotherapeutic effect of Mycobacterium vaccae on multi-drug resistant pulmonary tuberculosis. Chin. J. Tuberc. Resp. Dis. 23(2), 85-88 (2000).
27. Fan MY, Chen XR, Wang K et al.: Adjuvant effect of Mycobacterium vaccae on treatment of recurrent treated pulmonary tuberculosis: a meta-analysis. Chin. J. Evid. based Med. 7(6), 449-455 (2007).
28. Lijun X, Yanyan W, Xiaodong Z, Xiangdong G, Lifeng T, Haimimg W: Immunotherapeutical potential of Mycobacterium vaccae on M. tuberculosis infection in mice. Cell. Molec. Immunol. 6(1), 67-72 (2009).
29. Zhao XY, Xie QM, Chen JQ, Bian RL: [Effects of M. vaccae on airway contraction and inflammation in asthmatic guinea pigs] Zhonghua Jie He He Hu Xi Za Zhi 26(4), 218-222 (2003).
30. Wickremasinghe MI, Thomas LH, Friedland JS: Pulmonary epithelial cells are a source of IL-8 in the response to Mycobacterium tuberculosis: essential role of IL-1 from infected monocytes in a NF-κB dependent network. J. Immunol. 163, 3936-3947 (1999).
31. Zhang Y, Broser M, Cohen H et al.: Enhanced interleukin-8 release and gene expression in macrophages after exposure to Mycobacterium tuberculosis and its components. J. Clin. Invest. 95, 586-592 (1995).
32. Friedland JS, Hartley JC, Hartley CG, Shattock RJ, Griffin GE: Inhibition of ex vivo proinflammatory cytokine secretion in fatal Mycobacterium tuberculosis infection. Clin. Exp. Immunol. 100, 233-238 (1995).
33. Sadek MI, Sada E, Toossi Z, Schwander SK, Rich EA: Chemokines induced by infection of mononuclear phagocytes with mycobacteria and present in lung alveoli during active pulmonary tuberculosis. Am. J. Respir. Cell. Mol. Biol. 19, 513-521 (1998).
34. Ding AH, Nathan CF, Stuehr DJ: Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J. Immunol. 141, 2407-2412 (1988).
35. Flesch IE, Hess JH, Oswald IP, Kaufmann SH: Growth inhibition of Mycobacterium bovis by IFN-γ stimulated macrophages: regulation by endogenous tumor necrosis factor-α and by IL-10. Int. Immunol. 6, 693-700 (1994).
36. Flynn J, Goldstein MM, Chan J et al.: Tumor necrosis factor α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2, 561-572 (1995).
37. Gomez-Reino JJ, Carmona L, Valverde VR et al.: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 48, 2122-2127 (2003). (Pubitemid 36959191)
38. Rook GAW, Taverne J, Leveton C et al.: The role of γ interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology 62, 229-234 (1987). (Pubitemid 17140031)
39. Bekker LG, Moreira AL, Bergtold A et al.: Immunopathologic effects of tumor necrosis factor α in murine mycobacterial infection are dose dependent. Infect. Immun. 68, 6954-6961 (2000).
40. Hernandez-Pando R, Rook GA: The role of TNF-α in T-cell-mediated inflammation depends on the Th1/Th2 cytokine balance. Immunology 82, 591-595 (1994). (Pubitemid 2119263)
41. Hernandez-Pando R, Aguilar D, Hernandez ML, Orozco H, Rook G: Pulmonary tuberculosis in BALB/c mice with non-functional IL-4 genes: changes in the inflammatory effects of TNF-α and in the regulation of fibrosis. Eur. J. Immunol. 34, 174-183 (2004).
42. + T cells from patients with tuberculosis is related to the presence of pulmonary cavities. J. Infect. Dis. 181, 1194-1197 (2000).
43. Mazzarella G, Bianco A, Perna F et al.: T lymphocyte phenotypic profile in lung segments affected by cavitary and non-cavitary tuberculosis. Clin. Exp. Immunol. 132, 283-288 (2003).
44. Cadranel J, Philippe C, Perez J et al.: In vitro production of tumour necrosis factor and prostaglandin E2 by peripheral blood mononuclear cells from tuberculosis patients. Clin. Exp. Immunol. 81, 319-324 (1990).
45. Condos R, Rom WN, Liu YM, Schluger NW: Local immune responses correlate with presentation and outcome in tuberculosis. Am. J. Respir. Crit. Care Med. 157, 729-735 (1998).
46. Olobo JO, Geletu M, Demissie A et al.: Circulating TNF-α, TGF-β, and IL-10 in tuberculosis patients and healthy contacts. Scand. J. Immunol. 53, 85-91 (2001).
47. Nicholson S, Bonecini-Almeida Mda G, Lapa e Silva JR et al.: Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J. Exp. Med. 183, 2293-2302 (1996).
48. Kuo HP, Wang CH, Huang KS et al.: Nitric oxide modulates interleukin-1β and tumor necrosis factor-α synthesis by alveolar macrophages in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 161, 192-199 (2000).
49. Wang CH, Liu CY, Lin HC, Yu CT, Chung KF, Kuo HP: Increased exhaled nitric oxide in active pulmonary tuberculosis due to inducible NO synthase upregulation in alveolar macrophages. Eur. Respir. J. 11, 809-815 (1998).
50. Rich EA, Torres M, Sada E, Finegan CK, Hamilton BD, Toossi Z: Mycobacterium tuberculosis (MTB)-stimulated production of nitric oxide by human alveolar macrophages and relationship of nitric oxide production to growth inhibition of MTB. Tuber. Lung Dis. 78, 247-255 (1997).
51. Rockett KA, Brookes R, Udalova I, Vidal V, Hill AV, Kwiatkowski D: 1,25-dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line. Infect. Immunol. 66, 5314-5321 (1998).
52. Dlugovitzky D, Bay ML, Rateni L et al.: Influence of disease severity on nitrite and cytokine production by peripheral blood mononuclear cells from patients with pulmonary tuberculosis. Clin. Exp. Immunol. 122, 343-349 (2000).
53. Cassatella MA: The production of cytokines by polymorphonuclear neutrophils. Immunol. Today 16, 21 (1995).
54. Bogdan C, Schleicher U: Production of interferon-γ by myeloid cells - fact or fancy? Trends Immunology 27, 282-290 (2006).
55. Flynn JL, Chan J: Immunology of tuberculosis. Annu. Rev. Immunol. 19, 93-129 (2001).
56. Bottasso OA, Bay ML, Besedovsky H, del Rey A: The immuno-endocrine component in the pathogenesis of tuberculosis. Scand. J. Immunol. 66, 166-175 (2007).
57. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133-146 (2003).
58. Casanova JL, Abel L: Genetic dissection of immunity to mycobacteria: the human model. Annu. Rev. Immunol. 20, 581-620 (2002).
59. Hirsch CS, Yoneda T, Averill L et al.: Enhancement of intracellular growth of Mycobacterium tuberculosis in human monocytes by transforming growth factor-β1. J. Infect. Dis. 170, 1229-1237 (1994).
60. Warwick-Davies J, Lowrie DB, Cole PJ: Selective deactivation of human monocyte functions by TGF-β. J. Immunol. 155, 3186-3195 (1995).
61. Othieno C, Hirsch CS, Hamilton BD et al.: Interaction of Mycobacterium tuberculosis-induced transforming growth factor-β1 and interleukin-10. Infect. Immun. 67, 5730-5735 (1999).
62. Toossi Z, Gogate P, Shiratsuchi H et al.: Enhanced production of TGF-β by blood monocytes from patients with active tuberculosis and presence of TGF-β in tuberculous granulomatous lung lesions. J. Immunol. 154, 465-473 (1995).
63. Bogdan C, Vodovotz Y, Paik J, Xie QW, Nathan C: Mechanism of suppression of nitric oxide synthase expression by interleukin-4 in primary mouse macrophages. J. Leukoc. Biol. 55, 227-233 (1994).
64. + regulatory T cells. J. Exp. Med. 201, 1061-1067 (2005).
65. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L: TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 9, 1202-1208 (2003).
66. Bommireddy R, Doetschman T: TGF-β, T-cell tolerance and anti-CD3 therapy. Trends Mol. Med. 10, 3-9 (2004).
67. Belkaid Y: Regulatory T cells and infection: a dangerous necessity. Nat. Rev. Immunol. 7, 875-888 (2007).
68. Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A: Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am. J. Respir. Crit. Care Med. 173, 803-810 (2006).
69. Shabaana AK, Cooper AM: IL-23 and IL-17 in tuberculosis. Cytokine 41, 79-83 (2008).
70. Ito N, Nakamura H, Tanaka Y, Ohgi S: Lung carcinoma: analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry. Cancer 85(11), 2359-2367 (1999).
71. Stanford JL. Stanford CA, Baban B, Grange JM: Therapeutic vaccination for cancer, the potential value of mycobacterial products. Int. J. Pharmaceut. Med. 12, 191-195 (1992).
72. Maraveyas A, Baban B, Kennard D et al.: Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood leucocytes. Ann. Oncol. 10, 817-824 (1999).
73. Stansby G, Chan YC, Berwanger CS, Shurey S, Rook GA, Stanford JL: Prevention of experimental myointimal hyperplasia by immunomodulation. Eur. J. Vasc. Endovasc. Surg. 23, 23-28 (2002). • Demonstrates that treatment with M. vaccae reduces the severity of carotid myointimal hyperplasia following experimental balloon angioplasty.
74. Stanford J, Stanford C, Stansby G, Bottasso O, Bahr G, Grange J: The common mycobacterial antigens and their importance in the treatment of disease. Current Pharm. Des. 15, 1248-1260 (2009). •• Discusses the part played by immune recognition of the common antigens of mycobacteria, including their heat-shock proteins, in many diseases and the importance of cross-reactive host proteins as targets for M. vaccae immunotherapy.
75. O'Brien ME, Anderson H, Kaukel E et al.: SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life, without affecting survival, in patients with advanced non-small-cell lung cancer: Phase III results. Ann. Oncol. 15, 906-914 (2004).
76. Harper-Wynne CL, Sumpter K, Ryan C et al.: Addition of SRL172 to standard chemotherapy in small-cell lung cancer (SCLC) improves symptom control. Lung Cancer 47, 289-290 (2005).
77. Rook GAW, Lowry CA: The hygiene hypothesis and psychiatric disorders. Trends Immunology 29, 150-158 (2008).
78. Reiche EM, Morimoto HK, Nunes SM: Stress and depression-induced immune dysfunction: implications for the development and progression of cancer. Int. Rev. Psychiatry 17, 515-527 (2005).
79. Shahzada A, Binder CJ: Experimental immunotherapeutic approaches for athersclerosis. Clin. Immunol. (2009) (Epub ahead of print).
80. Schiavetti F, Thonnard J, Colao D, Boon T, Coulie PG: A human endogenous retroviral sequence encoding an antigen recognised on melanoma by cytolytic T lymphocytes. Cancer Res. 62, 5510-5516 (2002). • Firmly associates a human endogenous retrovirus in the etiology of melanoma and shows that a short amino-acid chain length is shared between the virus-induced antigens and some bacteria.
81. Bahr GM, Stanford JL, Rook GAW, Rees RJW, Abdelnoor AM, Frayha GJ: Two potential improvements to BCG and their effect on skin test reactivity in the Lebanon. Tubercle 67, 205-218 (1986).
82. Stanford JL, Terencio de las Aguas J, Torres P, Gervasioni BO, Ravioli R: Studies on the effects of a potential immunotherapeutic agent in leprosy patients. Health Cooperation Papers 7. Proceedings of the Fourth European Leprosy Symposium 201-206 (1987).